Objectives: This study was done to find out the comparative efficacy of Miglitol and Acarbose as add on therapy in patients of type 2 Diabetes Mellitus. Methods: This is a prospective, randomized, patient controlled, open label comparative study involving Type 2 diabetes patients, aged between 35-70 years of either sex of hyperglycaemic with PPBS __ampersandsigngt;180mg%, FBS __ampersandsignlt;200mg% even after treatment with glimeperide 4mg and Metfomin 2g for at least 3 months. Results: Miglitol produced a mean reduction of PPBS of 34.12 __ampersandsignplusmn; 4.89% and Acarbose produced a mean reduction of PPBS of 30.61 __ampersandsignplusmn; 5.86% whereas reduction in HbA1C with Miglitol was 0.58 __ampersandsignplusmn; 0.05 g% ad that of Acarbose was 0.47 __ampersandsignplusmn; 0.09 g% .The P value in both the cases were __ampersandsigngt; 0.05 signifying Miglitol to be better than Acarbose in terms of glycaemic controlin type 2 D.M. Conclusions: Type 2 Diabetes forms a significant share of the Diabetic load in India where cereals in the form of carbohydrates form the staple diet of most Indians. Thus __ampersandsignalpha; glucosidase inhibitors like Miglitol and acarbose are sure to play an important role as an add on therapy when first line drugs like sulphonylurea and biguanides fail to control the hyperglycaemia and they have minimum adverse effects, with more or less similar efficacy with Miglitol being better than Acarbose..